Kiniksa Pharmaceuticals Set to Announce Q4 Earnings on February 24

Kiniksa Pharmaceuticals International (NASDAQ: KNSA) is scheduled to release its earnings report for the fourth quarter of 2025 on February 24, 2026, before the market opens. Analysts anticipate the company will report earnings of $0.37 per share and revenue of approximately $200.855 million for the quarter. The earnings call will take place at 8:30 AM ET, providing investors with insights into the company’s performance and future outlook.

Market Performance and Insider Transactions

As of last Friday, Kiniksa’s stock opened at $47.77. The company has demonstrated a strong performance recently, with a 50-day moving average of $42.72 and a 200-day moving average of $39.41. Kiniksa holds a market capitalization of $3.62 billion, and its price-to-earnings ratio stands at 106.16. Over the past year, the stock has fluctuated between a low of $18.25 and a high of $47.86.

Recent insider trading activity has garnered attention. On February 12, Director Barry D. Quart sold 2,690 shares at an average price of $45.00, totaling $121,050. Following this sale, Quart now owns 12,546 shares valued at approximately $564,570, reflecting a 17.66% decrease in their ownership. Additionally, Chief Financial Officer Mark Ragosa sold 17,845 shares on February 9 for a total of $772,331.60, reducing his position by 59.62%.

Over the past 90 days, corporate insiders have sold a total of 123,823 shares valued at around $5,244,967. Notably, corporate insiders collectively own 53.48% of Kiniksa’s stock.

Analyst Ratings and Market Sentiment

Several financial institutions have recently adjusted their ratings for Kiniksa Pharmaceuticals. On January 13, Zacks Research downgraded the stock from a “hold” to a “strong sell.” Conversely, Canaccord Genuity Group initiated coverage with a “buy” rating and a price target of $62.00. The Goldman Sachs Group raised its price target from $45.00 to $55.00 while maintaining a “buy” rating.

Weiss Ratings reaffirmed a “hold (c)” rating on January 22, while Wedbush increased its price target from $48.00 to $50.00, assigning an “outperform” rating on January 13. Overall, seven investment analysts have assigned a “buy” rating to Kiniksa, with one holding and one selling, leading to a consensus rating of “Moderate Buy” and a target price of $53.71, according to MarketBeat.

Kiniksa Pharmaceuticals International, founded in 2013 and headquartered in Lexington, Massachusetts, focuses on developing therapies for patients with life-threatening immune-mediated diseases. The company’s lead product, Ilaris (canakinumab), is an interleukin-1β blocker used to treat various conditions, including systemic juvenile idiopathic arthritis and adult-onset Still’s disease.

As Kiniksa prepares to announce its earnings, stakeholders will be closely monitoring the developments, anticipating updates that may impact the company’s strategic direction and market position.